Reported 12 months ago
On July 1, 2024, Awesome Technology (stock code: 1784) saw strong buying interest as the Asia Biotech Summit is approaching, and both the National Health Insurance and Regenerative Medicine Act have passed for the next-generation gene sequencing (NGS), driving precision and cell therapy to be recent focal points. The stock price surged with specific buying interest, closing at 139.5 yuan, hitting a short-term high with a trading volume of 6,652 shares. Strong bullish momentum is seen as the Ministry of Health approved a collaboration with Linkou Chang Gung Hospital for an autologous adipose-derived stem cell therapy project, maintaining steady expansion. Moving forward with mesenchymal stem cells as the basis for entry into the global exosome contract manufacturing market, establishing joint relationships with international giants, developing comprehensive applications in medical aesthetics and new drugs. Subsidiary Awesome Technology Cell IntelliPharma will be listed on the OTC market in October.
Source: YAHOO